A Quick Look at Today's Ratings for Pyxis Oncology(PYXS.US), With a Forecast Between $7 to $10
Pyxis Oncology Is Maintained at Outperform by RBC Capital
H.C. Wainwright Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $7
RBC Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Raises Target Price to $10
Pyxis Oncology Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Pyxis Oncology Analyst Ratings
William Blair Initiates Pyxis Oncology(PYXS.US) With Hold Rating
Stifel Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $10
RBC Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $7
H.C. Wainwright Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $7
LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating
Pyxis Oncology Initiated at Overweight by Stephens & Co.
Stephens Initiates Pyxis Oncology(PYXS.US) With Buy Rating, Announces Target Price $13
LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating
Leerink Partners Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Announces Target Price $12
Leerink Partners维持Pyxis Oncology(PYXS.US)买入评级
RBC Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $7
Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS), Spruce Biosciences (SPRB) and Envista Holdings (NVST)
HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $7 Price Target
Pyxis Oncology Analyst Ratings
No Data
No Data